Strain differences in tamoxifen sensitivity of Sprague-Dawley and Fischer 344 rats

Anti-Cancer Drugs

Volumn 13, Issue 9, 2002, Pages 939-948

  Bailey, Jason A ^a   Nephew, Kenneth P ^a  

^a Indiana University School of Medicine   (United States)

Author keywords

Estradiol; Estrogen receptor; Rat strain; Tamoxifen; Uterus

Indexed keywords

4 HYDROXYTAMOXIFEN; COMPLEMENTARY DNA; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; RNA; 4-HYDROXYTAMOXIFEN; CELL RECEPTOR; DRUG DERIVATIVE; MESSENGER RNA; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL TYPE; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA PROBE; ENDOMETRIUM CANCER; FEMALE; GENE EXPRESSION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; RAT; STRAIN DIFFERENCE; UTERUS WEIGHT; ANIMAL; BIOSYNTHESIS; DRUG EFFECT; FISCHER 344 RAT; METABOLISM; ORGAN SIZE; SPECIES DIFFERENCE; SPRAGUE DAWLEY RAT; UTERUS; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; IMMUNOHISTOCHEMISTRY; MODELS, ANIMAL; ORGAN SIZE; RATS; RATS, INBRED F344; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, ESTROGEN; RNA, MESSENGER; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SPECIES SPECIFICITY; TAMOXIFEN; UTERUS;

EID: 0036813366     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200210000-00006     Document Type: Article

References (49)

1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-88.
2. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999; 91: 1829-46.
3. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86: 527-37.
4. Cohen I, Rosen DJ, Tepper R, et al. Ultrasonographic evaluation of the endometrium and correlation with endometrial sampling in postmenopausal patients treated with tamoxifen. J Ultrasound Med 1993; 12: 275-80.
5. McKean-Cowdin R, Feigelson HS, Pike MC, Coetzee GA, Kolonel LN, Henderson BE. Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype. Cancer Res 2001; 61: 848-9.
6. Haiman CA, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I. A polymorphism in CYP17 and endometrial cancer risk. Cancer Res 2001; 61: 3955-60.
7. Flaws JA, Bush TL. Racial differences in drug metabolism: An explanation for higher breast cancer mortality in blacks? Med Hypotheses 1998; 50: 327-9.
8. Flaws JA, Newschaffer CJ, Bush TL. Breast cancer mortality in black and in white women: A historical perspective by menopausal status. J Womens Health 1998; 7: 1007-15.
9. Maxwell GL, Risinger JI, Hayes KA, et al. Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers. Clin Cancer Res 2000; 6: 2999-3005.
10. Ham J, Parker MG. Regulation of gene expression by nuclear hormone receptors. Curr Opin Cell Biol 1989; 1: 503-11.
11. Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta: Regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res 2000; 2: 335-44.
12. Burch JB, Evans MI, Friedman TM, O'Malley PJ. Two functional estrogen response elements are located upstream of the major chicken vitellogenin gene. Mol Cell Biol 1988; 8: 1123-31.
13. Dennis AP, Haq RU, Nawaz Z. Importance of the regulation of nuclear receptor degradation. Front Biosci 2001; 6: D954-9.
14. Klinge CM. Estrogen receptor interaction with co-activators and co-repressors. Steroids 2000; 65: 227-51.
15. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 2000; 103: 843-52.
16. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L. Nuclear receptor coactivators and co-repressors. Mol Endocrinol 1996; 10: 1167-77.
17. Shibata H, Spencer TE, Onate SA, et al. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Prog Horm Res 1997; 52: 141-64; discussion 64-5.
18. Jenster G. Coactivators and co-repressors as mediators of nuclear receptor function: An update. Mol Cell Endocrinol 1998; 143: 1-7.
19. Hong H, Kohli K, Trivedi A, Johnson DL, Stallcup MR. GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc Natl Acad Sci USA 1996; 93: 4948-52.
20. Misiti S, Schomburg L, Yen PM, Chin WW. Expression and hormonal regulation of coactivator and co-repressor genes. Endocrinology 1998; 139: 2493-500.
21. Thenot S, Charpin M, Bonnet S, Cavailles V. Estrogen receptor cofactors expression in breast and endometrial human cancer cells. Mol Cell Endocrinol 1999; 156: 85-93.
22. Nephew KP, Long X, Osborne E, Burke KA, Ahluwalia A, Bigsby RM. Effect of estradiol on estrogen receptor expression in rat uterine cell types. Biol Reprod 2000; 62: 168-77.
23. Nephew KP, Osborne E, Lubet RA, Grubbs CJ, Khan SA. Effects of oral administration of tamoxifen, toremifene, dehydroepiandrosterone, and vorozole on uterine histomorphology in the rat. Proc Soc Exp Biol Med 2000; 223: 288-94.
24. Nephew KP, Ray S, Hlaing M, et al. Expression of estrogen receptor coactivators in the rat uterus. Biol Reprod 2000; 63: 361-7.
25. Fail PA, Anderson SA, Friedman MA. Response of the pituitary and thyroid to tropic hormones in Sprague-Dawley versus Fischer 344 male rats. Toxicol Sci 1999; 52: 107-21.
26. Spearow JL, O'Henley P, Doemeny P, et al. Genetic variation in physiological sensitivity to estrogen in mice. APMIS 2001; 109: 356-64.
27. Spady TJ, Pennington KL, McComb RD, Shull JD. Genetic bases of estrogen-induced pituitary growth in an intercross between the ACI and Copenhagen rat strains: Dominant Mendelian inheritance of the ACI phenotype. Endocrinology 1999; 140: 2828-35.
28. Roper RJ, Griffith JS, Lyttle CR, et al. Interacting quantitative trait loci control phenotypic variation in murine estradiol-regulated responses. Endocrinology 1999; 140: 556-61.
29. Lloyd RV. Estrogen-induced hyperplasia and neoplasia in the rat anterior pituitary gland. An immunohistochemical study. Am J Pathol 1983; 113: 198-206.
30. Wendell DL, Gorski J. Quantitative trait loci for estrogen-dependent pituitary tumor growth in the rat. Mamm Genome 1997; 8: 823-9.
31. Wendell DL, Herman A, Gorski J. Genetic separation of tumor growth and hemorrhagic phenotypes in an estrogen-induced tumor. Proc Natl Acad Sci USA 1996; 93: 8112-6.
32. Long X, Steinmetz R, Ben-Jonathan N, et al. Strain differences in vaginal responses to the xenoestrogen bisphenol A. Environ Health Perspect 2000; 108: 243-7.
33. Fan M, Long X, Bailey JA, et al. The activating enzyme of NEDD8 inhibits steroid receptor function. Mol Endocrinol 2002; 16: 315-30.
34. Chen D, Ma H, Hong H, et al. Regulation of transcription by a protein methyltransferase. Science 1999; 284: 2174-7.
35. Montano MM, Ekena K, Delage-Mourroux R, Chang W, Martini P, Katzenellenbogen BS. An estrogen receptor-selective co-regulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. Proc Natl Acad Sci USA 1999; 96: 6947-52.
36. Laborda J. 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Res 1991; 19: 3998.
37. Onate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995; 270: 1354-7.
38. Smith CL, O'Malley BW. Evolving concepts of selective estrogen receptor action: From basic science to clinical applications. Trends Endocrinol Metab 1999; 10: 299-300.
39. Karlsson S, Iatropoulos MJ, Williams GM, Kangas L, Nieminen L. The proliferation in uterine compartments of intact rats of two different strains exposed to high doses of tamoxifen or toremifene. Toxicol Pathol 1998; 26: 759-68.
40. Long X, Burke KA, Bigsby RM, Nephew KP. Effects of the xenoestrogen bisphenol A on expression of vascular endothelial growth factor (VEGF) in the rat. Exp Biol Med (Maywood) 2001; 226: 477-83.
41. da Costa GG, McDaniel-Hamilton LP, Heflich RH. Marques MM, Beland FA. DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives. Carcinogenesis 2001; 22: 1307-15.
42. Stanley LA, Carthew P, Davies R, Higginson F, Martin E, Styles JA. Delayed effects of tamoxifen in hepatocarcinogenesis-resistant Fischer 344 rats as compared with susceptible strains. Cancer Lett 2001; 171: 27-35.
43. Cole RC, Flaws JA, Bush TL. SERMs: The benefits of estrogen without the risks? J Womens Health 1998; 7: 1187-9.
44. Yamasaki K, Sawaki M, Takatsuki M. Strain sensitivity differences in the Hershberger assay. Reprod Toxicol 2001; 15: 437-40.
45. Shepel LA, Gould MN. The genetic components of susceptibility to breast cancer in the rat. Prog Exp Tumor Res 1999; 35: 158-69.
46. Koh SS, Chen D, Lee YH, Stallcup MR. Synergistic enhancement of nuclear receptor function by p160 coactivators and two coactivators with protein methyltransferase activities. J Biol Chem 2001; 276: 1089-98.
47. Norris JD, Fan D, Stallcup MR, McDonnell DP. Enhancement of estrogen receptor transcriptional activity by the coactivator GRIP-1 highlights the role of activation function 2 in determining estrogen receptor pharmacology. J Biol Chem 1998; 273: 6679-88.
48. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung I., Horwitz KB. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the co-repressors N-CoR or SMRT. Mol Endocrinol 1997; 11: 693-705.
49. Webb P, Nguyen P, Shinsako J, et al. Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol Endocrinol 1998; 12: 1605-18.